🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

I have been fielding a lot of calls from my #medonc colleagues around availability of #microbiome modulating studies for #kidneycancer at City of Hope (in particular, #CBM588). The following are the two studies we have enrolling currently (limited slots remaining): 1.

At #AACR25, #myeloma specialist Urvi Shah will take part in a session to discuss the potential of a whole foods, plant-based diet to improve health outcomes in people with #cancer. #nutrition Memorial Sloan Kettering Cancer Center AACR Learn more: bit.ly/4iF3wLB

Look forward to presenting at the dietary forum - testing diet with the rigor of drug at 5 pm today at #AACR25 AACR with Marcus Goncalves and Jennifer McQuade Come join us for this discussion! Memorial Sloan Kettering Cancer Center MSK Department of Medicine

Congratulations to Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 on being recognized by The OncLive.com Giants of Cancer Care program. Currently Chief of Myeloma Service at Memorial Sloan Kettering Cancer Center , Dr. Usmani is also a member of The International Myeloma Foundation's Scientific Advisory Board. onclive.com/view/giants-of…

We had a fascinating interview with Urvi Shah of Memorial Sloan Kettering Cancer Center at #IBC2025, in which she gave an insight into the potential of non-drug interventions, specifically diet and lifestyle, in SMM and MGUS. Watch here: 👉 ow.ly/9tvQ50VP4go 👈 #HemOnc #MMSM #Hematology

Latest feature out now! 🎉 With insight from Urvi Shah, Janine M. Joseph, Francesca Castro, MS RD CDN, Jens Hillengass, Manni Mohyuddin, & Aaron Goodman - “Papa Heme”, we explored the association between dietary patterns & blood cancer risk and how dietary research in cancer is conducted. ➡️ buff.ly/VZj1VzZ

We're pleased to announce the 2025 Oncologic Toxicity Management Symposium Memorial Sloan Kettering Cancer Center. This year’s program will highlight emerging therapies that are shaping the future of oncology care, along with practical strategies for managing treatment-related toxicities. Learn more

This is great! Kudos Ahmad Abuhelwa Ethan Basch et al on fascinating myeloma work. When comparing PFS & OS in #MMsm RCTs stratified by PROs, the patients with worse baseline physical fxn benefit the most from CD38 mAb inclusion. I often say #lessismore in myeloma - not here!

This was a privilege to work on. Big thanks to all of our co-authors and collaborators for supporting the effort!

This may be the most discussed abstract ASCO. Much talk about ivermectin as treatment for cancer, esp on social media. But what are the data? To my knowledge, there are no actual clinical trial data - until now. The New York Times The Wall Street Journal FORTUNE OncoAlert LARVOL

That's the world's literature on ivermectin in advanced cancer. 8 pts with TNBC getting ICI + ivermectin, 1 response (same rate as ICI alone, in other trials), avg PFS of 2.5 m. So, at present, there is no evidence for meaningful clinical activity of ivermectin in cancer.

Breaking News: Prothena Corporation has announced that the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in patients with Mayo Stage IV AL #amyloidosis failed to meet its primary endpoint. Learn more: arci.org/negative-affir…

Ultimate review on Myeloma bone disease! Open access too doi.org/10.1016/j.blre… #mmsm Vincent Rajkumar Rahul Banerjee, MD, FACP @urvishahMD Ben Derman Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Luciano J Costa Robert Z. Orlowski Shaji Kumar Anup Joseph Devasia

1/ 🚨 Leading to #asco2025, our educational ebook is out: “Practical Guide to Clinical Trial Accessibility: Making Trial Participation a Standard of Care” Proud to be a co-author of this multi-stakeholder perspective on reducing barriers to trial participation. 📖

Excellent work in Leukemia Journal by Arwa Bohra (she/her) Shaji Kumar Vincent Rajkumar Mayo Myeloma: For myeloma #MMsm, 5% CPCs = PCL. But manual smears not always done or reliable. On PB flow, 1.16% CPCs ≈ 5% by PB smear. % CPCs exist on continuum (any are bad), but nice to have cutoff!

My top 5 picks for plasma cell disorders abstracts at #ASCO25 #mmsm in no order of preference: 1) 7505: Trispecific targeting BCMA/GPRC5D, this is by the far the most disruptive advance in early development! 2) 7507: Are we curing RRMM with BCMA CART? 3) 7508: Next Gen BCMA CART

A successful investigator initiated randomized clinical trial is not as easy as it sounds. Many years of work, many barriers to overcome. Time: Idea to Approval: 1-2 years Approval to Opening: 1 year Opening to Accrual: 3-5 years Accrual to Result: 2-5 years Result to

🚨Today kicks off #ASCO25. Follow along on our MSK social channels from May 30-June 3 for onsite updates, and read about the latest #cancerresearch from our MSK experts here: bit.ly/43lJ7qA (ASCO)

Excited to present our research on GLP-1 receptor agonists and their impact on weight loss across cancer types at the 2025 ASCO Annual Meeting! 🙌 A huge thank you to MSK’s incredible leaders—Drs. Urvi Shah, Sherry Shen, and Neil Iyengar—for their unwavering mentorship and

Great to see dietary and exercise data presented ASCO #ASCO25 being discussed in The Wall Street Journal wsj.com/health/healthc…